Guillain–Barré Syndrome

Guillain-Barré syndrome (GBS) is a heterogeneous group of acquired immune-mediated demyelinating neuropathies affecting the peripheral nervous system. The hallmark of GBS is an autoimmune response where the body's immune system, typically tasked with defending against pathogens, mistakenly targets components of the peripheral nerves. The primary targets are often the myelin sheath, the lipid-rich insulating layer that facilitates rapid saltatory conduction of nerve impulses, or sometimes the axonal membrane itself.

This immune-mediated damage leads to inflammation and demyelination, disrupting nerve signal transmission. The clinical presentation varies, with different subtypes of GBS characterized by specific antibodies and electrophysiological findings, such as the common acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), and acute motor and sensory axonal neuropathy (AMSAN).

The precise etiology of GBS remains elusive, but it is widely understood to be triggered by an antecedent event, most commonly an infection. Approximately two-thirds of GBS cases follow an infection, with Campylobacter jejuni being the most frequent bacterial trigger, particularly for AMAN and AMSAN subtypes, due to molecular mimicry where bacterial antigens resemble host nerve components. Viral infections, such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), and Zika virus, are also implicated.

Less commonly, GBS can be triggered by surgery, trauma, or vaccination. The mechanism involves the immune system mounting a response to the pathogen or foreign substance, but due to similarities in molecular structure, it cross-reacts with peripheral nerve antigens, initiating the autoimmune cascade. Understanding these triggers is crucial for potential preventative strategies and early recognition.

The onset of GBS is typically rapid, with symptoms developing over hours to a few weeks. The hallmark is ascending, symmetrical muscle weakness, often beginning in the lower extremities and progressing upwards. Sensory disturbances, such as paresthesias (tingling or numbness), and pain, particularly in the back, are common early symptoms.

A critical complication is respiratory muscle weakness, which can necessitate mechanical ventilation in up to 15% of patients. Autonomic dysfunction, including fluctuations in heart rate and blood pressure, can also occur, posing life-threatening risks. Diagnosis relies on a combination of clinical presentation, neurological examination findings, and exclusion of other causes.

Lumbar puncture to analyze cerebrospinal fluid often reveals albuminocytologic dissociation (high protein with normal cell count), and nerve conduction studies demonstrate characteristic patterns of demyelination or axonal damage.

Prompt treatment is vital for improving outcomes in GBS. The primary immunomodulatory therapies are intravenous immunoglobulin (IVIg) and plasmapheresis (plasma exchange). IVIg involves infusing high doses of antibodies from healthy donors, which is thought to block the harmful antibodies attacking the nerves.

Plasmapheresis removes circulating autoantibodies from the blood. Supportive care is paramount, focusing on respiratory support, cardiovascular monitoring, pain management, and prevention of complications like deep vein thrombosis and pressure sores. While the majority of patients recover, the recovery process can be lengthy, ranging from weeks to years.

Approximately one-third of individuals experience some degree of permanent neurological deficit, such as residual weakness or fatigue. The global mortality rate is around 7.5%, underscoring the seriousness of the condition and the importance of timely and effective medical intervention.

Guillain-Barré syndrome is a rare neurological disorder, with an incidence rate of approximately 1 to 2 cases per 100,000 people annually. It affects individuals of all ages, though it is more common in adults and has a slight male predominance. The syndrome was first described in 1916 by French neurologists Georges Guillain and Jean Alexandre Barré, along with physician André Strohl, during World War I.

Their initial observations of two soldiers with ascending paralysis provided the foundation for understanding this distinct neurological entity. Since then, extensive research has elucidated its autoimmune nature, identified various subtypes, and developed effective treatments, transforming it from a poorly understood and often fatal condition into one with a significantly improved prognosis, though challenges in complete recovery and understanding its triggers persist.